Grasp the latest information from Olin and understand the new trends in the industry.
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
On December 11, 2025, Mr. Matthew Fosbery, Deputy Commercial Consul of Australia in Chengdu and Trade & Investment Commissioner of Austrade, and Ms. Wang Ming, Commercial Officer of Austrade, visited Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) for inspection and exchanges, and had in-
On March 17, 2020, the Cash-in of the First Batch of Project Policies and the Symposium of Biological Enterprises under “Measures to Strengthen Technological Breakthroughs and Material Support for COVID-19 Prevention and Control in Chengdu High-tech Zone” was held in Chengdu High-tech Zone to support 18 enterprises and 2 provincial medical institutions that deeply participated in epidemic prevention and control and made practical contributions.